Core Viewpoint - The company maintains a "Buy" rating for Hong Kong stocks and raises the target price to HKD 20, while upgrading the A-share rating to "Buy" with a target price of RMB 32 [1][5]. Financial Performance - For Q4 2024, the company's revenue reached RMB 12.276 billion, reflecting a year-on-year increase of 6.4%, aligning with the upper end of the previous profit forecast [2]. - Adjusted net profit attributable to shareholders was RMB 1.607 billion, down 15.6% year-on-year, closely matching the median of the prior profit forecast [2]. - Q4 2024 revenue was RMB 3.458 billion, showing a year-on-year increase of 16.1% and a quarter-on-quarter increase of 7.6% [2]. - The adjusted non-IFRS net profit for Q4 2024 was RMB 499 million, up 1.7% year-on-year and 19.7% quarter-on-quarter [2]. Segment Performance - CMC (Contract Manufacturing and Consulting) services led revenue growth in Q4 2024, achieving a year-on-year growth rate of 26.9% and a quarter-on-quarter growth rate of 26.4% [3]. - Laboratory services also showed significant growth, with a year-on-year increase of 14.9%, although it experienced a slight decline of 1.0% quarter-on-quarter [3]. - Clinical research services saw a year-on-year growth of 9.5% and a quarter-on-quarter growth of 12.4%, despite ongoing pricing pressures [3]. - The CGT (Cell and Gene Therapy) segment continued to show weakness, with both revenue and gross margin declining year-on-year and quarter-on-quarter [3]. Future Outlook - The company expects revenue growth of 10%-15% in 2025, primarily driven by CMC and laboratory services [4]. - Management anticipates potential improvements in profit margins due to sustained revenue growth and no significant additional costs expected [4]. - The new order value for CMC services is projected to grow over 35% year-on-year, while laboratory services are expected to see a growth of over 20% year-on-year [4]. Target Price Adjustments - The target price for Hong Kong stocks has been raised to HKD 20, while the A-share target price has been adjusted to RMB 32, reflecting an 80% premium over the Hong Kong target price [5]. - The adjusted non-IFRS net profit estimates for 2025E and 2026E are RMB 1.79 billion and RMB 2.26 billion, respectively, due to slight adjustments in gross margin forecasts [5].

Financial Performance - Pharmaron reported a revenue increase of 25% year-over-year, reaching approximately RMB 2.5 billion in the latest quarter[18]. - The company's operating revenue for 2024 reached ¥12,275,774,875.03, representing a 6.39% increase compared to ¥11,537,996,314.78 in 2023[23]. - Net profit attributable to shareholders for 2024 was ¥1,793,350,814.50, marking a 12.01% increase from ¥1,601,096,033.08 in 2023[23]. - The company reported a basic earnings per share of ¥1.0133 for 2024, up 12.18% from ¥0.9033 in 2023[23]. - The company achieved operating revenue of 1,227,577.49 million yuan, a year-on-year increase of 6.39%[42]. - The company reported a decline in cash flow from operating activities, totaling 257,665.64 million yuan, down 6.42% year-on-year[42]. - The company reported a net cash flow from operating activities of ¥2,576,656,397.08 in 2024, down 6.42% from ¥2,753,538,934.89 in 2023[23]. - The company reported a significant increase in revenue, achieving a total of $1.5 billion, representing a 20% year-over-year growth[176]. Research and Development - Pharmaron's R&D investment increased by 30% to RMB 500 million, focusing on new drug development and innovative technologies[18]. - The company has expanded its capabilities in antibody-drug conjugates (ADC) and antisense oligonucleotides (ASO) as part of its research and development strategy[15]. - The company is actively exploring the application of artificial intelligence and machine learning in process chemistry R&D and quality management to enhance CDMO service efficiency[53]. - The company is committed to enhancing its ESG initiatives, focusing on sustainable practices in its operations[18]. - The company is focused on enhancing its research and development capabilities to better meet customer needs[115]. - The company is committed to improving high-quality, diverse biomedical databases and constructing reliable AI models, ensuring the sustainability of AI-enabled drug development[134]. Market Expansion and Strategy - Pharmaron is actively pursuing market expansion in Europe and North America, aiming to increase its global footprint[18]. - The company is continuously exploring market expansion opportunities and potential mergers and acquisitions to enhance its competitive position[15]. - The company plans to strengthen its leadership in small molecule R&D services while expanding into new drug modalities such as ADCs and peptides, with a focus on building an end-to-end service platform[121]. - The company aims to enhance collaboration across its multi-therapy platform, focusing on seamless integration in drug development stages and improving service quality through interdisciplinary cooperation[125]. - The company plans to expand its market presence in Southeast Asia, targeting a 20% market share by 2025[175]. Corporate Governance and Compliance - The company emphasizes the importance of accurate financial reporting, with all board members present for the approval of the annual report[3]. - The company has established a governance structure that complies with relevant laws and regulations, ensuring transparency in information disclosure[147]. - The company received an "A" rating in the information disclosure assessment from the Shenzhen Stock Exchange, reflecting its commitment to high-quality and transparent reporting[142]. - The company has established a comprehensive risk management framework to address various financial risks[1]. - The company is committed to maintaining a high standard of compliance with international regulations and quality standards to ensure the integrity of its services[126]. Employee Development and Corporate Culture - The company emphasizes a strong commitment to employee development and customer satisfaction, integrating personal career growth into the overall corporate strategy[73]. - The company has established a comprehensive talent management system to attract and retain skilled professionals, crucial for sustaining its competitive edge[128]. - The company has implemented a comprehensive compensation policy to attract and retain talent, including competitive salaries, bonuses, and various benefits[198]. - Training programs are tailored for different management levels, focusing on leadership development and performance improvement[199][200]. - The company emphasizes mental health and well-being through various employee support programs[198]. Financial Strategy and Investments - The company plans to distribute a cash dividend of 2 RMB per 10 shares, totaling approximately 356.11 million RMB for the 2023 fiscal year[144]. - The company will repurchase 9,608,288 A shares for a total amount of approximately 200.09 million RMB in 2024[145]. - The company has not utilized any raised funds during the reporting period[112]. - The company is considering strategic acquisitions to bolster its market position, with a budget of $100 million allocated for potential deals[176]. - The company is implementing hedging strategies to manage foreign exchange risks effectively[131]. Environmental and Social Responsibility - The company is actively responding to the national "dual carbon" strategy, focusing on reducing its environmental impact and promoting green transformation within its operations[142]. - The company reduced greenhouse gas emissions by 21% in 2024 compared to 2023, achieving its annual carbon reduction target[47]. - The company is committed to enhancing its ESG initiatives, focusing on sustainable practices in its operations[18]. Risk Management - The company has established a comprehensive risk management framework to address various financial risks[1]. - The company is actively monitoring international policy changes and trade dynamics to mitigate risks associated with geopolitical uncertainties[130]. - The company acknowledges potential risks in the drug development service market due to fluctuations in investment and budget changes from multinational pharmaceutical companies[127]. - The company faces risks related to intellectual property protection and is enhancing its confidentiality measures to safeguard client information[129].

Financial Performance - The company reported a net profit of 1.793 billion yuan for 2024, representing a year-on-year increase of 11.99% compared to 1.601 billion yuan in 2023 [1] - Revenue for 2024 reached 12.276 billion yuan, up 6.4% from 11.538 billion yuan in 2023 [1] - Basic earnings per share increased to 1.0133 yuan, a rise of 12.18% from 0.9033 yuan in the previous year [1] - The return on equity (ROE) slightly decreased to 13.70% from 13.91% in 2023 [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 99.14136 million shares, accounting for 57.62% of the circulating shares, with a decrease of 2.17455 million shares compared to the previous period [2] - HKSCC NOMINEES LIMITED remains the largest shareholder with 30.15020 million shares, representing 17.52% of the total share capital [3] - Shenzhen Xinchongkang Investment Partnership holds 26.08280 million shares, making up 15.16% of the total [3] Dividend Distribution - The company announced a dividend distribution of 0.2 yuan per share (including tax) [4]

Financial Performance - For the year ended December 31, 2024, total revenue reached RMB 12,275.8 million, an increase of approximately RMB 737.8 million or 6.4% compared to the previous year[3] - The profit attributable to equity holders of the parent company was approximately RMB 1,793.4 million, representing a growth of 12.0% from RMB 1,601.1 million in 2023[3] - The net cash flow from operating activities was approximately RMB 2,576.7 million, a decrease of about 6.4% compared to RMB 2,753.5 million in the prior year[3] - The gross profit for the year was RMB 4,149.3 million, reflecting a slight increase of 1.3% from RMB 4,094.8 million in 2023[5] - The group reported a pre-tax profit of RMB 2,091,263 thousand for the year ended December 31, 2024, compared to RMB 1,837,887 thousand in 2023, reflecting an increase of approximately 13.8%[17] - Total revenue for the year ended December 31, 2024, was RMB 12,275,775 thousand, an increase from RMB 11,537,996 thousand in 2023, representing a growth of approximately 6.4%[21] Dividends and Earnings - The board proposed a final dividend of RMB 2.0 per share, amounting to a total of approximately RMB 354.2 million[3] - The proposed final dividend for the year ending December 31, 2024, is RMB 2.0 per 10 shares, totaling approximately RMB 354,186,000 (tax included)[34] - The basic earnings per share for the year ending December 31, 2024, is RMB 1.014, compared to RMB 0.903 for 2023, reflecting an increase of approximately 12.3%[37] Assets and Liabilities - Total non-current assets increased to RMB 16,319.2 million from RMB 15,602.3 million in 2023[8] - Current assets decreased to RMB 7,608.2 million from RMB 10,874.4 million in the previous year[8] - Total liabilities decreased from RMB 9,584.2 million in 2023 to RMB 5,480.5 million in 2024[9] - The total equity attributable to equity holders of the parent company increased to RMB 13,619.3 million from RMB 12,556.8 million in the previous year[9] Revenue Breakdown - The revenue breakdown by region for 2024 shows North America at RMB 7,852,729 thousand, Europe at RMB 2,271,934 thousand, and mainland China at RMB 1,847,332 thousand[18] - The laboratory services segment generated revenue of RMB 7,046,875 thousand, while the CMC services segment contributed RMB 2,988,773 thousand, indicating strong performance across these divisions[17] - Total revenue from the European market increased significantly from RMB 1,844,397 thousand in 2023 to RMB 2,271,934 thousand in 2024, marking a growth of approximately 23.2%[18] - Laboratory services revenue grew to RMB 7,046,875 thousand in 2024, up 5.8% from RMB 6,660,117 thousand in 2023[21] Research and Development - Research and development costs amounted to RMB 469.3 million, up from RMB 448.3 million in the previous year[5] - The company operates 21 R&D centers and production bases across China, the UK, and the US, enhancing its global drug development services[44] - The company has established a bioanalytical platform in China and the US to support global clinical trials for small molecules and biologics[50] - The company is currently managing 1,062 ongoing clinical trial projects, including 94 Phase III trials and 407 Phase I/II trials[67] Operational Efficiency and Technology - The company emphasizes enhancing operational efficiency and service capabilities to meet market demands[44] - The company has begun applying artificial intelligence tools in laboratory chemistry and plans to continue expanding investments in AI and automation to enhance research efficiency[61] - The company is actively exploring the application of AI and machine learning in process chemistry research and production optimization to improve CDMO service efficiency[64] - The company achieved significant progress in digitalization and intelligence within its clinical sector, integrating multiple AI applications across various business areas[68] Market Outlook and Strategy - The company aims to become a global leader in multi-therapy drug development services, focusing on small molecules, large molecules, and cell and gene therapies[44] - The company plans to enhance its large molecule drug discovery and CDMO service capabilities in 2025, establishing a quality system that adheres to the highest international regulatory standards[144] - The company aims to strengthen its cell and gene therapy service platform by leveraging synergies between its U.S. and U.K. operations, gradually expanding its customer base and operational efficiency[145] - The company recognizes the risk of declining demand in the drug development service market due to fluctuations in investment and budget changes from multinational pharmaceutical companies[149] Employee and Talent Management - The company has a total of 21,370 employees as of December 31, 2024, compared to 20,295 employees as of December 31, 2023, indicating a growth of approximately 5.3% in workforce[159] - The company is committed to attracting and retaining top talent to maintain its competitive edge in providing high-quality services[149] - The company will optimize its human resources management system to enhance talent attraction, assessment, training, and motivation mechanisms[150] Compliance and Risk Management - The company has established an audit committee consisting of three independent non-executive directors, ensuring compliance with applicable accounting principles and standards[176] - The company is actively monitoring changes in pharmaceutical policies and is committed to meeting regulatory requirements to avoid operational disruptions[152] - The company faces risks from international policy changes and trade tensions, which could adversely affect its operations in overseas markets[153] Shareholder Actions - The company repurchased a total of 9,608,288 A-shares at a total cost of approximately RMB 200.1 million during the reporting period, with all shares canceled by December 25, 2024[160] - The company repurchased 7,263,300 H-shares at a total cost of approximately HKD 99.8 million from December 2024 to January 2025, which are held as treasury shares[162] - The company conducted a series of repurchases and redemptions of convertible bonds totaling approximately USD 573.1 million during the reporting period[166] Strategic Partnerships and Acquisitions - The company signed a strategic cooperation agreement with AstraZeneca Investment (China) for integrated services in drug discovery and development, increasing its investment in the AstraZeneca fund to RMB 191 million, representing 8.46% of the total subscription[120] - The company completed the acquisition of approximately 78.5% of Shanghai Jiying Intelligent Technology Co., Ltd. and a controlling transaction with Zhejiang Haixin Zhihui Technology Co., Ltd. in February 2025[68] - The company plans to acquire a 51.39% stake in Hai Xin Zhi Hui for approximately RMB 185.0 million, expected to complete by February 2025, enhancing its capabilities in digital tumor patient management[172]

Revenue Projections - The estimated revenue for 2024 is projected to be between RMB 1,199,951.62 million and RMB 1,234,565.60 million, representing a year-on-year growth of 4% to 7%[4]. - The fourth quarter revenue is expected to grow by 4% quarter-on-quarter and 13% year-on-year, supported by the timely delivery of CMC services[11]. Profit Expectations - The net profit attributable to shareholders is expected to be between RMB 172,918.37 million and RMB 185,727.14 million, indicating a year-on-year increase of 8% to 16%[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to decline by 24% to 29%, estimated between RMB 107,484.80 million and RMB 115,054.15 million[4]. - The adjusted net profit under non-IFRS is expected to be between RMB 156,081.32 million and RMB 165,598.47 million, reflecting a decrease of 13% to 18% compared to the previous year[5]. - The overall performance is influenced by a combination of increased revenue and non-recurring gains, leading to a net profit growth of 8% to 16%[12]. Non-Recurring Gains - Non-recurring gains and losses for the period are estimated to be between RMB 66,000 million and RMB 71,000 million, significantly higher than RMB 8,722.56 million in the previous year[12]. - The company has completed the sale of its stake in PROTEOLOGIX, resulting in a non-recurring gain of approximately RMB 56,000 million[7]. Order and Client Activity - The company anticipates a 20% increase in new order amounts year-on-year, driven by a recovery in global client inquiries and visits[11]. Financial Data Status - The financial data presented is preliminary and has not been audited by an accounting firm[10].

Financial Performance - Revenue for Q3 2024 reached 3,212,811,697.13 yuan, a year-on-year increase of 10.02%[3] - Net profit attributable to shareholders in Q3 2024 was 308,396,080.13 yuan, a year-on-year decrease of 12.62%[3] - Total assets as of the end of Q3 2024 were 23,570,041,501.34 yuan, a year-on-year decrease of 10.98%[3] - Total operating revenue for the current period is 8,817,275,052.00 yuan, an increase from 8,560,256,911.27 yuan in the previous period[24] - Operating profit for the current period is 1,627,236,356.80 yuan, up from 1,328,483,021.07 yuan in the previous period[24] - Net profit attributable to the parent company's shareholders is 1,421,799,112.63 yuan, compared to 1,139,038,016.10 yuan in the previous period[25] - Basic earnings per share (EPS) for the current period is 0.8028, up from 0.6430 in the previous period[25] - Total comprehensive income for the current period is 1,430,086,645.22 yuan, compared to 1,107,456,956.68 yuan in the previous period[25] - Net profit for the current period is 1,369,206,716.49 yuan, compared to 1,134,523,142.41 yuan in the previous period[25] - Total comprehensive income attributable to the parent company's shareholders is 1,478,341,755.57 yuan, up from 1,112,499,103.26 yuan in the previous period[25] Revenue Breakdown by Service and Region - Laboratory services revenue for the first three quarters of 2024 was 5,218,670,210.75 yuan, a year-on-year increase of 2.95%[4] - CMC (small molecule CDMO) services revenue for the first three quarters of 2024 was 1,976,627,679.48 yuan, a year-on-year increase of 3.29%[4] - Revenue from North American clients in the first three quarters of 2024 was 573,067.48 million yuan, a year-on-year increase of 4.29%[5] - Revenue from Chinese clients in the first three quarters of 2024 was 132,879.79 million yuan, a year-on-year decrease of 12.14%[5] - Revenue from European clients (including the UK) in the first three quarters of 2024 was 152,731.20 million yuan, a year-on-year increase of 15.74%[5] - The company's overseas laboratories and factories saw a revenue decline of 1.34% in the first three quarters of 2024, accounting for 12.78% of total revenue[5] New Orders and Growth - New orders in the first three quarters of 2024 increased by over 18% year-on-year, with CMC services new orders growing by over 30%[6] Cash Flow and Financial Position - Cash and cash equivalents decreased by RMB 3.86 billion, a 66.19% drop compared to the beginning of the year[10] - Prepaid expenses increased by RMB 7.76 million, a 43.59% rise due to higher prepayments for raw material purchases[10] - Other receivables grew by RMB 51.75 million, a 45.74% increase mainly due to higher tax refund subsidies[10] - Deferred tax assets increased by RMB 54.30 million, a 35.44% rise due to higher deferred tax assets related to deductible losses[10] - Investment income surged by RMB 567.42 million, a 1,158.41% increase due to gains from the disposal of non-current financial assets and convertible bond repurchases[10] - Fair value change losses decreased by RMB 62.32 million, a 155.03% drop due to reduced gains from biological assets and derivative financial instruments[10] - Asset disposal losses increased by RMB 23.92 million, a 9,732.09% rise due to higher non-current asset disposal losses[11] - Non-operating income decreased by RMB 2.19 million, a 64.56% drop due to reduced government subsidies[11] - Income tax expenses increased by RMB 66.25 million, a 35.54% rise due to higher profit[11] - Total assets decreased to 23.57 billion yuan from 26.48 billion yuan at the beginning of the period[21][22] - Current assets decreased to 7.10 billion yuan from 10.87 billion yuan at the beginning of the period[21] - Non-current assets increased to 16.47 billion yuan from 15.60 billion yuan at the beginning of the period[21] - Total liabilities decreased to 9.54 billion yuan from 13.24 billion yuan at the beginning of the period[22] - Current liabilities increased to 4.16 billion yuan from 3.65 billion yuan at the beginning of the period[22] - Non-current liabilities decreased to 5.39 billion yuan from 9.58 billion yuan at the beginning of the period[22] - Owner's equity increased to 14.03 billion yuan from 13.24 billion yuan at the beginning of the period[22] - Cash and cash equivalents decreased to 2.00 billion yuan from 5.92 billion yuan at the beginning of the period[21] - Accounts receivable increased to 2.27 billion yuan from 2.24 billion yuan at the beginning of the period[21] - Inventory increased to 1.20 billion yuan from 1.01 billion yuan at the beginning of the period[21] - Sales of goods and services received cash of 8,940,386,810.41 yuan, an increase from 8,345,874,274.78 yuan in the previous period[26] - Cash received from tax refunds was 417,480,501.78 yuan, up from 384,922,168.66 yuan in the previous period[26] - Total cash inflow from operating activities was 9,481,564,856.83 yuan, compared to 8,954,356,730.64 yuan in the previous period[26] - Cash paid for goods and services was 1,740,077,789.56 yuan, an increase from 1,602,776,669.59 yuan in the previous period[26] - Cash paid to employees and for employee benefits was 4,309,827,312.87 yuan, up from 3,912,340,413.31 yuan in the previous period[26] - Net cash flow from operating activities was 1,770,502,528.88 yuan, a decrease from 2,029,402,975.72 yuan in the previous period[26] - Net cash flow from investing activities was -897,439,031.21 yuan, an improvement from -1,807,866,341.75 yuan in the previous period[26] - Net cash flow from financing activities was -4,785,948,104.84 yuan, a significant decrease from 431,485,182.20 yuan in the previous period[27] - The net increase in cash and cash equivalents was -3,857,571,108.40 yuan, compared to 663,129,877.44 yuan in the previous period[27] - The ending balance of cash and cash equivalents was 1,931,543,560.63 yuan, down from 2,022,842,617.58 yuan in the previous period[27] Shareholder and Investment Information - The top shareholder, HKSCC NOMINEES LIMITED, holds 16.87% of the shares, totaling 301,501,968 shares[12] - China Bank holds 25,892,311 shares, accounting for 1.45% of the total shares[14] - Industrial and Commercial Bank of China holds 13,655,593 shares, accounting for 0.76% of the total shares[14] - The company acquired approximately 78.5% equity of Shanghai Jiyin Intelligent Technology Co., Ltd. for RMB 43 million[17] - The company completed the first tranche of equity transfer payment and obtained control of Shanghai Jiyin in July 2024[17] - All first batch of HKD 300 million zero-coupon convertible bonds due in 2026 have been repurchased or redeemed and canceled[18] - The second batch of RMB 1,916 million zero-coupon USD-settled convertible bonds due in 2026 were repurchased or redeemed and delisted in June 2024[18] - The company's subsidiary Pharmaron (Hong Kong) International Limited invested an additional USD 7 million in PharmaGend, holding 35% of its shares[18] - The company increased its investment in AstraZeneca Fund to RMB 191 million, accounting for 8.46% of the fund's total subscribed capital[18] - The company completed the repurchase of shares through centralized bidding on July 26, 2024[19] - The company adjusted the 2021, 2022, and 2023 A-share restricted stock incentive plans on August 28, 2024[19] Operating Costs and Expenses - Total operating costs for the current period are 7,773,877,243.72 yuan, up from 7,354,768,450.44 yuan in the previous period[24] - Research and development expenses for the current period are 332,252,436.76 yuan, up from 296,764,121.85 yuan in the previous period[24]

Financial Performance - The company's operating revenue for Q3 2024 was CNY 3,212,811,697.13, representing a 10.02% increase compared to the same period last year[4]. - Net profit attributable to shareholders for Q3 2024 was CNY 308,396,080.13, a decrease of 12.62% year-on-year[4]. - The adjusted net profit attributable to shareholders under non-IFRS was CNY 417,128,142.56, down 13.20% compared to the previous year[4]. - Revenue from laboratory services for the first three quarters of 2024 was CNY 5,218,670,210.75, with a gross margin of 44.76%, up 2.95% year-on-year[5]. - Revenue from CMC (small molecule CDMO) services was CNY 1,976,627,679.48, with a gross margin of 30.82%, reflecting a 3.29% increase year-on-year[5]. - The company reported a significant increase in other comprehensive income by 1,170.63%, reaching 51,712,554.95 CNY compared to -4,830,087.99 CNY at the beginning of the year[10]. - The total income tax expense increased by 35.54%, amounting to 252,668,803.97 CNY compared to 186,420,334.57 CNY in the same period last year[11]. - The company reported a basic earnings per share of ¥0.8028, up from ¥0.6430 in the previous period, representing an increase of approximately 24.8%[34]. Assets and Liabilities - The total assets at the end of Q3 2024 were CNY 23,570,041,501.34, a decrease of 10.98% from the end of the previous year[4]. - The company's total current assets decreased from RMB 10.874 billion at the beginning of the period to RMB 7.098 billion at the end of the period[26]. - Non-current assets increased from RMB 15.602 billion at the beginning of the period to RMB 16.472 billion at the end of the period, indicating growth in long-term investments[27]. - Total liabilities at the end of the period amounted to ¥9,543,999,010.21, a decrease from ¥13,238,666,497.83 at the beginning of the period[30]. - The company’s total non-current liabilities were ¥5,387,955,744.22, compared to ¥9,584,190,645.48 at the beginning of the period, indicating a significant reduction[30]. - The total number of common shareholders at the end of the reporting period is 76,716[12]. Cash Flow - The company’s cash flow from operating activities for the year-to-date was CNY 1,770,502,528.88, down 12.76% year-on-year[4]. - Operating cash inflow for the current period reached CNY 8,940,386,810.41, an increase of 7.15% compared to CNY 8,345,874,274.78 in the previous period[35]. - Net cash flow from operating activities was CNY 1,770,502,528.88, down 12.73% from CNY 2,029,402,975.72 in the previous period[36]. - Cash inflow from investment activities totaled CNY 2,369,036,263.63, up from CNY 2,107,544,066.88 in the previous period[37]. - Net cash flow from investment activities was -CNY 897,439,031.21, an improvement from -CNY 1,807,866,341.75 in the previous period[37]. - Cash inflow from financing activities was CNY 793,674,688.64, down from CNY 1,445,088,087.27 in the previous period[38]. - Net cash flow from financing activities was -CNY 4,785,948,104.84, compared to a positive CNY 431,485,182.20 in the previous period[38]. Shareholder Information - The top 10 shareholders hold a combined 53.88% of the shares, with HKSCC NOMINEES LIMITED holding the largest share at 16.87%[12]. - The second-largest shareholder, Shenzhen Xinchongkang Investment Partnership, holds 14.59% of the shares[12]. - Pharmaron Holdings Limited, the third-largest shareholder, owns 10.10% of the shares[12]. - The total number of shares held by the top 10 unrestricted shareholders is 1,000,000,000[13]. - The largest unrestricted shareholder, HKSCC NOMINEES LIMITED, holds 301,501,968 shares[13]. - The total number of restricted shares at the beginning of the period was 64,260,000, with 6,986,213 shares released during the period[17]. - The number of shares held by the largest shareholder, Lou Xiaoqiang, decreased from 51,041,250 to 45,405,037 due to lock-up restrictions[17]. - The company has no preferred shareholders as of the reporting period[17]. - There are no known relationships or concerted actions among the top shareholders, except for specific connections mentioned[14]. Investments and Acquisitions - The company acquired approximately 78.5% of Shanghai Jiying Intelligent Technology Co., Ltd. for a total investment of RMB 43 million, enhancing its capabilities in AI technology[19]. - The company successfully repurchased and canceled all of its first batch of USD 300 million zero-coupon convertible bonds, with a net amount raised of approximately RMB 3.776 billion from the issuance[20]. - The company invested an additional USD 7 million in PharmaGend Global Medical Services Pte. Ltd., increasing its stake to 35%[21]. - The company signed a strategic cooperation agreement with AstraZeneca Investment (China) Co., Ltd., committing to a total investment of RMB 91 million in the AstraZeneca Fund, representing 8.46% of the total subscription amount[23]. Other Financial Metrics - The company recognized a one-time loss of RMB 44,016 thousand due to business closure during the reporting period[46]. - The company reported a foreign exchange-related loss of RMB 32,273 thousand and unrealized gains of RMB (468,170) thousand from equity investments[46]. - The company experienced a 41.74% increase in credit impairment losses, totaling -24,846,953.62 CNY compared to -17,530,101.09 CNY in the previous year[11]. - The company reported a decrease in operating income by 64.56%, amounting to 1,201,135.59 CNY compared to 3,389,121.43 CNY in the same period last year[11]. - Research and development expenses increased to ¥332,252,436.76 from ¥296,764,121.85, marking a rise of approximately 11.9%[32].

Financial Performance - For the six months ended June 30, 2024, the company reported total revenue of RMB 5,604.5 million, a decrease of approximately RMB 35.7 million or 0.6% compared to the same period in 2023[8]. - The gross profit for the same period was RMB 1,848.1 million, reflecting a decline of 9.3% from RMB 2,037.4 million in the previous year[8]. - Profit attributable to equity holders of the parent increased by approximately 41.6% to RMB 1,113.4 million, compared to RMB 786.1 million for the six months ended June 30, 2023[9]. - The net cash flow from operating activities was approximately RMB 1,099.7 million, down 14.1% from RMB 1,280.2 million in the same period last year[9]. - The company achieved a net profit attributable to shareholders of RMB 1,113.4 million, an increase of 41.6% year-on-year[12]. - The company’s adjusted net profit under IFRS was RMB 690.3 million, a decrease of 25.9% year-on-year[12]. - The company reported a total of RMB 50,026,000 in current liabilities related to derivative financial instruments as of June 30, 2024, compared to RMB 26,931,000 as of December 31, 2023, showing an increase of approximately 85.5%[164]. - The total comprehensive income for the period was RMB 1,050,416 thousand, compared to RMB 821,211 thousand in the previous year, indicating a growth of 28%[124]. Revenue Breakdown - In Q2 2024, the company achieved revenue of RMB 2,933.7 million, representing a 9.9% increase compared to Q1 2024, indicating a recovery in the global biopharmaceutical investment and financing environment[11]. - Revenue from European customers (including the UK) was RMB 945.6 million, a year-on-year increase of 10.0%, accounting for 16.9% of total revenue[12]. - Revenue from North American customers was RMB 3,668.2 million, accounting for 14.1% of total revenue[12]. - The laboratory services segment generated revenue of RMB 3,371.2 million, a slight decrease of 0.3% year-on-year, with a gross margin of 44.0%[13]. - CMC (small molecule CDMO) services generated revenue of RMB 1,175.7 million, a decrease of 6.0% year-over-year; Q2 2024 revenue was RMB 593.6 million, reflecting a 2.0% increase from Q1 2024[14]. - Clinical research services achieved revenue of RMB 843.3 million, a 4.7% increase year-over-year; Q2 2024 revenue was RMB 451.7 million, up 15.4% from Q1 2024[15]. - The company's revenue from macromolecule and cell gene therapy services reached RMB 211.2 million, representing a 5.5% increase compared to the same period last year[16]. Customer Base and Market Position - The company served over 2,200 global customers in the first half of 2024, with multi-segment customers contributing RMB 3,987.9 million, representing 71.2% of total revenue[12]. - The company added over 360 new customers, contributing RMB 161.2 million to total revenue[12]. - 97% of the company's revenue comes from a large, diverse, and loyal repeat customer base, enhancing sustainable growth[31]. - The global biopharmaceutical industry is showing signs of recovery, with financing amounts for biotech companies returning to growth, indicating a preliminary revival in customer demand[32]. Operational Efficiency and Strategy - The company is focused on building a multi-therapy, full-process integrated service platform, aiming to become a global leader in drug development services[10]. - The company continues to strengthen its international capabilities to provide cross-disciplinary, cross-regional, and cross-border collaborative service solutions[10]. - The company is committed to improving management efficiency and service capabilities to meet market and customer demands[10]. - The company emphasizes continuous investment in technology and innovation, particularly in AI, to support its research and development capabilities[22]. - The company has established a comprehensive drug research and development service platform, enhancing its competitive advantage in the pharmaceutical industry[26]. Sustainability and Corporate Governance - The company’s scientific carbon targets were officially verified by SBTi, indicating a commitment to sustainability and carbon reduction initiatives[12]. - The company is committed to environmental protection, health, safety, and intellectual property rights, ensuring client trust and recognition[31]. - The company has established a DEI (Diversity, Equity, and Inclusion) management structure to ensure effective implementation of DEI policies across governance and operational levels[50]. - The company has actively responded to national initiatives for renewable energy use, with domestic parks already implementing green electricity applications and overseas parks utilizing biomass energy and photovoltaic power generation[63]. Human Resources and Employee Engagement - The company has established a comprehensive training system, including the Kanglong Academy, to enhance employee skills and research capabilities[31]. - The company emphasizes talent acquisition and retention, aiming to attract top drug development talent and enhance its internal training platform[38]. - The company has implemented a systematic training program for all employees and contractors to ensure understanding of company policies and job responsibilities[51]. - The company provides 10 days of paid parental leave and flexible part-time work arrangements in the UK and US locations[54]. Financial Position and Investments - As of June 30, 2024, the total current assets amounted to approximately RMB 7,071.2 million, compared to RMB 10,874.4 million as of December 31, 2023[20]. - The total liabilities to total assets ratio (leverage ratio) improved to 40.5% as of June 30, 2024, down from 50.0% as of December 31, 2023[20]. - The company completed the sale of its stake in Proteologix, Inc. to Johnson & Johnson for approximately USD 102 million, receiving a net payment of USD 86.195 million after transaction costs[22]. - The company has outstanding bank loans totaling RMB 5,179,140,000, with RMB 852,040,000 due within one year, compared to RMB 727,412,000 in the previous year, indicating a year-over-year increase of 17.1%[171]. Risks and Challenges - The company faces regulatory risks related to drug development and production, which could impact its operations if it fails to meet compliance requirements[44]. - The company is exposed to foreign exchange risks primarily related to USD, GBP, and EUR, with a significant portion of its revenue coming from USD-denominated sales[45]. - The competitive landscape is expected to intensify as more competitors enter the market, impacting various factors such as service quality and pricing[47].

Financial Performance - Total revenue for the six months ended June 30, 2024, was approximately RMB 5,604.5 million, a decrease of about RMB 35.7 million or 0.6% compared to the same period in 2023[2] - Profit attributable to equity holders of the parent company was approximately RMB 1,113.4 million, an increase of about 41.6% compared to RMB 786.1 million in the same period of 2023[2] - Net cash flow from operating activities was approximately RMB 1,099.7 million, a decrease of about 14.1% compared to RMB 1,280.2 million in the same period of 2023[2] - Gross profit for the six months ended June 30, 2024, was approximately RMB 1,848.1 million, a decrease of 9.3% compared to RMB 2,037.4 million in the same period of 2023[2] - The company recorded other income and gains of RMB 776.3 million, significantly up from RMB 131.7 million in the same period of 2023[3] - The group reported a pre-tax profit of RMB 1,226,851,000, compared to RMB 908,525,000 for the same period in 2023, marking an increase of approximately 35%[16] - The company’s adjusted net profit under non-IFRS was RMB 690.3 million, down from RMB 931.9 million in the previous year[53] Revenue Breakdown - For the six months ended June 30, 2024, total revenue reached RMB 5,604,463,000, a slight decrease of 0.6% compared to RMB 5,640,118,000 for the same period in 2023[16] - The laboratory services segment generated revenue of RMB 3,371,177,000, accounting for approximately 60% of total revenue, while the CMC (small molecule CDMO) services segment contributed RMB 1,175,747,000[16] - The clinical research services segment achieved revenue of RMB 843,269,000, reflecting an increase of 4.7% from RMB 805,193,000 in the prior year[16] - Revenue from North America was RMB 3,668,223,000, a decrease of 0.2% from RMB 3,675,469,000 in the previous year[18] - Revenue from Europe increased by 10% to RMB 945,577,000 from RMB 859,776,000 in 2023[18] - Revenue from mainland China decreased by 13.2% to RMB 842,603,000 from RMB 970,977,000 in 2023[18] Expenses and Costs - The group incurred administrative expenses of RMB 841,221,000, which is consistent with the previous year's expenses of RMB 845,440,000[16] - Research and development costs amounted to RMB 207,798,000, up from RMB 182,179,000 in the same period last year, representing an increase of approximately 14.1%[16] - The company reported a total of RMB 2,137,594,000 in employee costs, an increase from RMB 2,029,553,000 in 2023[27] Assets and Liabilities - Total assets as of June 30, 2024, amounted to RMB 25,340.7 million, compared to RMB 25,186.5 million as of December 31, 2023[7] - Current assets decreased to RMB 7,071.2 million from RMB 10,874.4 million as of December 31, 2023, indicating a significant reduction in liquidity[7] - Non-current liabilities decreased to RMB 5,414.3 million from RMB 9,584.2 million as of December 31, 2023, reflecting a reduction in long-term debt obligations[8] - Trade receivables as of June 30, 2024, totaled RMB 2,179.3 million, down from RMB 2,242.2 million at the end of 2023[30] - Trade payables amounted to RMB 503.0 million, an increase from RMB 412.2 million at the end of 2023[32] Dividends and Shareholder Returns - The company decided not to declare any interim dividend for the six months ended June 30, 2024[2] - The company declared a final dividend of RMB 0.2 per share for the year ended December 31, 2023, totaling RMB 353,963,000[28] - The company plans to distribute a final dividend of RMB 0.2 per share to A-share and H-share shareholders, with the record date set for July 8, 2024[160] Employee and Workforce - The company employed a total of 20,342 staff, with 89.7% in R&D, production technology, and clinical services[38] - As of June 30, 2024, the company employed 20,342 staff, an increase from 20,295 employees on December 31, 2023, indicating a growth in workforce[149] - The company has a workforce of 18,241 R&D, production technology, and clinical service personnel across China, the UK, and the US, ensuring high-quality service delivery[121] Strategic Initiatives and Growth - The company continues to focus on expanding its integrated pharmaceutical R&D services platform globally, enhancing its capabilities in drug innovation[12] - The company has signed new contracts with a total value that increased by over 15% compared to 2023[34] - The company is collaborating with over 650 hospitals and clinical trial centers across more than 140 cities in China, with ongoing projects exceeding 1,500[47] - The company has established a leading integrated pharmaceutical R&D service platform, providing comprehensive services for drug discovery, preclinical, and clinical development[106] - The company aims to enhance its integrated drug development service platform, focusing on small molecule research and expanding into large molecule and gene therapy services[129] Risks and Challenges - The pharmaceutical research and development outsourcing industry may experience slower growth due to fluctuations in investment sentiment, which could negatively impact the company's performance[138] - The company is at risk of losing qualified research and development personnel due to competition from pharmaceutical and biotech firms, which could affect service quality[138] - The company faces risks related to intellectual property protection, as unauthorized disclosure of client information could lead to significant reputational damage[141] - Regulatory compliance is critical, as failure to meet standards could result in operational suspension or penalties[142] - The company is exposed to foreign exchange risks, particularly with the US dollar, British pound, and euro, and will continue to engage in hedging transactions to reduce this risk[144] Incentive Plans - Under the 2021 A-share incentive plan, the maximum number of restricted A-shares to be issued is 1,741,950, representing approximately 0.10% of the total issued shares as of June 30, 2024[64] - The 2022 A-share incentive plan allows for the issuance of a maximum of 3,304,800 restricted A-shares, accounting for approximately 0.18% of the total issued shares as of June 30, 2024[76] - The 2023 A-share incentive plan was approved by shareholders on June 21, 2023, aiming to enhance corporate governance and retain key personnel[85] Acquisitions and Investments - The company has completed the sale of its stake in PROTEOLOGIX, INC. to Johnson & Johnson for approximately USD 102 million, receiving a net payment of USD 86.195 million after transaction costs[102] - The company has acquired approximately 78.5% of Shanghai Jiying Intelligent Technology Co., Ltd. for a total investment of RMB 43.0 million, enhancing its capabilities in AI technology[102] - The company has signed a strategic cooperation agreement with AstraZeneca Investment (China) Co., Ltd. for a comprehensive investment in the AstraZeneca Fund, increasing its total investment in the fund to RMB 191 million, accounting for 8.46% of the total subscription[104]

Financial Performance - Revenue for the first half of 2024 reached $1.2 billion, representing a 15% year-over-year growth[2] - Net profit for the first half of 2024 was $180 million, a 12% increase compared to the same period last year[2] - Revenue for the first half of 2024 was RMB 5,604.46 million, a slight decrease of 0.63% year-over-year[15] - Net profit attributable to shareholders increased by 41.64% to RMB 1,113.40 million compared to the same period last year[15] - Adjusted non-IFRS net profit attributable to shareholders decreased by 25.93% to RMB 690.27 million[22] - The company expects full-year 2024 revenue to grow by 12-15%, reaching $2.5-2.6 billion[4] - Revenue from clients using multiple business segments accounted for 71.16% of total revenue, amounting to RMB 3,987.94 million[23] - Revenue from North American clients was RMB 3,668.22 million, accounting for 65.45% of total revenue, a slight decrease of 0.20% year-over-year[24] - Revenue from European clients (including the UK) increased by 9.98% to RMB 945.58 million, accounting for 16.87% of total revenue[24] - The company served over 2,200 global clients, with over 360 new clients contributing RMB 161.24 million, or 2.88% of total revenue[23] - Overseas subsidiaries delivered revenue of RMB 736.83 million, a 3.99% increase year-over-year, accounting for 13.15% of total revenue[25] - Laboratory services revenue for the first half of 2024 was 3,371.1768 million yuan, a slight decrease of 0.27% year-over-year, with a gross margin of 44.46%, down 0.59 percentage points[27] - CMC (small molecule CDMO) services revenue for the first half of 2024 was 1,175.7473 million yuan, a decrease of 6.04% year-over-year, with a gross margin of 28.30%, down 4.16 percentage points[28] - Clinical research services revenue for the first half of 2024 was 843.2694 million yuan, an increase of 4.73% year-over-year, with a gross margin of 12.55%, down 4.43 percentage points[30] - The company's large molecule and cell & gene therapy services generated revenue of 211.21 million yuan, a year-on-year increase of 5.49%, with Q2 2024 revenue reaching 119.78 million yuan, a 31.00% increase from Q1 2024[32] - The gross margin for large molecule and gene therapy CDMO services was -31.34% in H1 2024 due to ongoing construction and operational costs[32] - Revenue for the first half of 2024 was RMB 5,604,463,354.87, a slight decrease of 0.63% compared to the same period last year[48] - Operating costs increased by 3.96% to RMB 3,733,284,838.30, while sales expenses decreased by 3.02% to RMB 122,949,469.45[48] - R&D investment increased by 14.06% to RMB 207,797,841.87, reflecting the company's commitment to innovation[48] - Net cash flow from operating activities decreased by 14.10% to RMB 1,099,735,310.22, while net cash flow from financing activities saw a significant decrease of 825.39% to RMB -4,653,026,429.44[48] - Laboratory services accounted for the largest portion of revenue at RMB 3,371,176,816.35, with a gross margin of 44.46%[49] - CMC (small molecule CDMO) services revenue decreased by 6.04% to RMB 1,175,747,332.83, with a gross margin of 28.30%[49] - Clinical research services revenue increased by 4.73% to RMB 843,269,367.02, but the gross margin decreased by 4.43% to 12.55%[49] - The company's cash and cash equivalents decreased by 414.22% to RMB -3,506,304,159.12, primarily due to increased cash outflows from financing activities[48] - The company's investment income was RMB 634,095,077.59, accounting for 51.68% of total profit, mainly from the disposal of non-current financial assets and the redemption of convertible bonds[50] - Cash and cash equivalents decreased by RMB 350.63 million, a drop of 59.44% compared to the end of the previous year[52] - Accounts receivable increased by 1.01% to RMB 89 million, representing 9.48% of total assets[52] - Inventory increased by 1.34% to RMB 1.188 billion, accounting for 5.17% of total assets[52] - Fixed assets grew by 7.63% to RMB 7.398 billion, representing 32.17% of total assets[52] - Prepayments increased by RMB 8.2274 million, a rise of 46.20%, mainly due to increased prepayments for raw material procurement[52] - Long-term prepaid expenses increased by RMB 184.6683 million, a growth of 35.48%, primarily due to new operating lease property improvements[52] - Trading financial assets decreased by RMB 260.8939 million, a drop of 41.95%, mainly due to the redemption of low-risk bank wealth management products[52] - Long-term equity investment increased by 0.46% to RMB 734.2411 million, representing 3.19% of total assets[52] - The company's investment in the UK subsidiary, Kanglong (UK), accounted for 13.78% of the company's net assets, with a net profit of RMB 35.0722 million for the reporting period[54] - Total investment during the reporting period was RMB 2.7588 billion, an increase of 4.93% compared to the same period last year[57] - The company's financial assets measured at fair value had a total initial investment cost of 2,128,576,048.84 yuan, with a cumulative investment income of 573,579,951.29 yuan[58] - The company's other financial assets had an initial investment cost of 1,861,000,000.00 yuan, with a cumulative investment income of 10,888,387.92 yuan[58] - The company's other financial assets had an initial investment cost of 267,576,048.84 yuan, with a cumulative investment income of 562,691,563.37 yuan[58] - The company's financial derivatives had a cumulative fair value change of -27,649,894.23 yuan[58] - The company's entrusted wealth management products had a total amount of 132,500 million yuan, with an outstanding balance of 41,814.97 million yuan[60] - The company's forward foreign exchange contracts had an initial investment amount of 669,919.2 million yuan, with a fair value change of -5,180.51 million yuan[61] - The company's forward foreign exchange contracts had a final amount of 327,832.8 million yuan, accounting for 25.19% of the company's net assets at the end of the reporting period[61] - The company's actual loss from forward contracts and related foreign exchange transactions was 4,585.70 million yuan[61] - The company's financial derivatives are valued based on the market price of the USD/CNY spot rate at the end of each month[62] - The company's financial derivatives investment was approved by the board of directors on March 28, 2024, and by the shareholders' meeting on June 6, 2024[62] - Kanglong Chem (Ningbo) Technology Development Co., Ltd., a wholly-owned subsidiary, reported total assets of 2.297 billion yuan, net assets of 1.793 billion yuan, operating income of 871.86 million yuan, and net profit of 147.85 million yuan[66] Business Operations and Strategy - The company's CDMO business contributed $400 million, accounting for 33% of total revenue[2] - The company plans to expand its production capacity in the second half of 2024, with an investment of $200 million[4] - The number of active clients increased by 10% to 1,500, with 30% of revenue coming from new clients[2] - The company's gross margin remained stable at 35%, reflecting efficient cost management[2] - The company issued $300 million in zero-coupon convertible bonds due in 2026[7] - New orders signed in the first half of 2024 increased by over 15% year-over-year[22] - The company participated in 666 drug discovery projects in the first half of 2024, an increase of 16 projects year-over-year[27] - Laboratory services new orders increased by over 10% year-over-year, with biological sciences accounting for over 53% of laboratory services revenue[27] - CMC (small molecule CDMO) services new orders increased by over 25% year-over-year, with 78% of revenue coming from existing drug discovery service clients[28] - The company's laboratory services team consists of 9,377 employees, including nearly 6,000 laboratory chemistry researchers[28] - The company's CMC (small molecule CDMO) services team consists of 4,228 employees, with 695 drug molecules or intermediates involved in projects[29] - The company's clinical research services team consists of 3,899 employees, with a 96-bed early-stage clinical research center in Maryland, USA[31] - The number of ongoing clinical trial service projects reached 1,112, including 77 Phase III trials, 409 Phase I/II trials, and 626 other clinical trials[32] - The company provided efficacy determination and release services for 21 cell and gene therapy products from 17 clients, including 9 clinical-stage projects and 2 commercial projects[32] - The company's Carlsbad in vivo toxicology research center in California has been partially operational, supporting cell and gene therapy products, ophthalmic products, and medical devices[33] - The global biotech financing market showed signs of recovery, with increased funding for biotech companies, indicating a potential rebound in client demand[33] - The company's integrated platform offers end-to-end services from drug discovery to clinical development, with a strong presence in China, the US, and the UK[35] - The company's chemical technology platform covers the entire small molecule drug R&D process, from compound design to GMP-compliant commercial production[37] - The company's DMPK/ADME global service network includes advanced technologies like radioactive isotope analysis, enhancing its position as a leading integrated service provider[37] - Established a comprehensive drug discovery to clinical proof-of-concept integrated service platform, covering multiple disciplines such as drug molecule design, compound library synthesis, and clinical data statistics[38] - Built a domestic clinical research platform offering end-to-end services for Phase I-IV clinical development, enhancing competitiveness through internal growth and external acquisitions[38] - Developed a gene therapy "lab analysis-IND study-process development & production" integrated platform, including GLP/GCP/GMP-compliant facilities in the US and UK[40] - Operates 21 entities globally (11 overseas), leveraging international operations to provide customized services and solutions across key pharmaceutical regions[40] - Acquired advanced production equipment and leased a Singapore-based formulation factory, expanding global CDMO service capabilities[42] - Focused on innovation in chemical and biological technologies, including fluid chemistry, biocatalysis, and gene editing platforms[43] - Maintains a workforce of 18,241 R&D, production, and clinical service personnel across China, the UK, and the US as of June 30, 2024[44] - Strengthened international operations through strategic acquisitions, integrating top-tier talent and facilities into the integrated R&D service platform[41] - Collaborated with US-based clinical pharmacology teams to support domestic clients in filing IND applications and conducting first-in-human studies in the US[40] - Enhanced global service network by investing in PharmaGend and acquiring Strides Pharma Global's production assets in Singapore[42] - The company added over 360 new clients in the first half of 2024, with over 97% of revenue coming from repeat clients[46] - The company aims to strengthen its leadership in small molecule R&D services and expand into new drug fields such as oligonucleotides, peptides, antibodies, ADC, and cell and gene therapy products[69] - Kanglong Chem plans to enhance its CMC (small molecule CDMO) service competitiveness by integrating commercial capabilities in China, the UK, and the US, and improving resource utilization and production efficiency[69] - The company will focus on improving the integration of its clinical development platform, particularly enhancing collaboration between US and Chinese teams to support the global expansion of Chinese innovative drugs[70] - Kanglong Chem will continue to develop its large molecule and cell and gene therapy service platforms, expanding service content and increasing operational efficiency[70] - The company plans to strengthen talent acquisition and retention, particularly in drug R&D, and enhance internal training programs to support long-term sustainable development[71] - Kanglong Chem will further enhance the synergy of its integrated platform by improving management efficiency and reducing costs[71] - The company will intensify its business and market development efforts, particularly in overseas markets, by deepening customer relationships and expanding service offerings[72] - Kanglong Chem will prioritize production safety and intellectual property security, ensuring high-quality products and services while adhering to international quality standards[73] - The company plans to deepen its CRO+CDMO integrated platform and expand its customer base to strengthen its competitive position[79] - The company will invest heavily in new technologies and consider acquisitions to enhance its service capabilities[80] - Maintaining high service quality is crucial, as any failure could lead to client loss and reputational damage[80] Environmental, Social, and Governance (ESG) - The company's ESG initiatives reduced carbon emissions by 15% compared to the previous year[7] - The company's ESG rating was upgraded to AA, and it was included in the 2024 A-share listed companies ESG Excellence TOP100 and Corporate Governance (G) Dimension Best Practice TOP20[26] - The company adheres to environmental protection laws and regulations in China, the UK, and the US, including the Clean Water Act and Clean Air Act[96] - Completed environmental self-acceptance for the application of biological in vitro test models to study drug efficacy and druggability platform project on April 13, 2023[98] - Obtained the first pollutant discharge permit on October 14, 2019, with the current permit valid until October 13, 2027[98] - Completed environmental self-acceptance for the new drug R&D outsourcing service base expansion project in Tianjin in November 2022[99] - Received approval for hazardous waste transfer to Hebei Province for utilization on January 24, 2024, with approval number Jinkaihuan Guzhuan [2024]10[100] - Received approval for hazardous waste transfer to Shandong Province for utilization on March 14, 2024, with approval number Jinkaihuan Guzhuan [2024]30[100] - Reapplied and obtained approval for the pollutant discharge permit on June 6, 2024[100] - Approved for the environmental impact assessment of the Xi'an R&D Center (Phase II) project on December 30, 2015, with approval number Jingkaihuan Pifu [2015]235[101] - Obtained the pollutant discharge permit for Xi'an on December 14, 2020, valid until December 13, 2023[101] - Completed environmental self-acceptance for the new drug R&D outsourcing platform expansion project in Beijing on August 20, 2020[97] - Approved for the environmental impact assessment of the new drug R&D outsourcing platform in vitro pharmacokinetics project on November 20, 2020, with approval number Jinghuan Shenzi [2020]0093[97] - The company completed the environmental protection acceptance monitoring report for the 120 tons/day laboratory wastewater treatment project at Kanglong Huacheng (Xi'an) New Drug Technology Co., Ltd., which was approved by the expert group[102] - The company obtained a pollutant discharge permit for Kanglong Huacheng (Xi'an) New Drug Technology Co., Ltd., valid until December 13, 2028[102] - The company completed the environmental impact assessment and acceptance monitoring reports for multiple projects in the Hangzhou Bay Life Science Park, including the bio-pharmaceutical R&D base and animal laboratory public service platform[103] - The company obtained environmental impact assessment approvals for the second phase of the Hangzhou Bay Life Science Industrial Park bio-pharmaceutical R&D service base project[103] - The company completed the environmental impact assessment and acceptance monitoring reports for the annual production of 47 tons and 25 tons of pharmaceutical intermediates at Kanglong Huacheng (Shaoxing) Pharmaceutical Co., Ltd.[104] - The company obtained a pollutant discharge permit for Kanglong Huacheng (Shaoxing) Pharmaceutical Co., Ltd., valid until October 10, 2026[104] - The company completed the environmental protection facility acceptance report for the annual production of 25 tons of pharmaceutical intermediates at Kanglong Huacheng (Shaoxing) Pharmaceutical Co., Ltd.[105] - The company obtained environmental impact assessment approvals for the new drug development technology service platform project at Kanglong Huacheng (Beijing) Technology Development Co., Ltd.[106] - The company completed the environmental impact assessment and adjustment report for the innovation center bio-pharmaceutical innovation platform project at Kanglong Huacheng (Ningbo) Bio-pharmaceutical Co., Ltd.[106] - The company reported the discharge of major pollutants, including CODcr, PH, NH3-N, and SS, at Kanglong Huacheng (Beijing) New Drug Technology Co., Ltd., with no超标排放情况[107] - Average concentration of VOCs emissions is 1.435 mg/m³, with a total emission of 11.28 tons[108] - Average concentration of nitrogen oxides emissions is 17 mg/m³, with a total emission of 0.2737 tons[108] - Total emission of waste organic solvents is 2094.547 tons[108] - Total emission of contaminated waste packaging is 606.45 tons[108] - Total emission of waste activated carbon is 14.836 tons[108] - Total emission of waste silica gel is 64.676 tons[108] - Total emission of laboratory waste is 20.475 tons[108] - Total emission of waste oil is 0 tons[109] - Total emission of expired and invalid drugs is 0 tons[109] - Total emission of COD